Publication date: 2024-09-15
In this research update, Dr. Patrick Nemechek discusses a pattern he has been watching since SARS-CoV-2 (COVID) emerged: some patients develop a persistent, long-haul inflammatory phase that does not return to baseline, and that ongoing inflammation appears tied to a distinct form of intestinal permeability (“leaky gut”).
In Dr. Nemechek’s framework, this matters because intestinal barrier disruption can amplify systemic immune activation. He also outlines why this COVID-associated pattern may not respond to the same interventions he uses when intestinal permeability is driven primarily by small intestinal bacterial overgrowth (SIBO)/dysbiosis, and why he instead emphasizes glutamine support in these cases.
Educational medical disclaimer: This article summarizes an educational video and Dr. Nemechek’s clinical observations and interpretations. It is not medical advice and is not a substitute for individualized evaluation, diagnosis, or treatment from your clinician.
Short-term COVID vs. long COVID: the inflammation curve Dr. Nemechek is concerned about
Dr. Nemechek highlights a key difference between short-term COVID and long COVID (long haulers): in short-term infection, the inflammatory response rises and then returns toward baseline as the patient recovers. In long COVID, he describes a more chronic inflammatory phase that persists instead of resolving. In his view, this sustained inflammation can drive downstream problems—one of which is a particular type of gut barrier breakdown.
Two “leaky gut” patterns: leaking between seams vs. cell death–related permeability
Dr. Nemechek contrasts two mechanisms of intestinal permeability:
1) SIBO/dysbiosis-associated permeability (“between the seams”)
In his prior work, he describes a common pathway in which there is excessive bacteria in the small intestine—what he refers to as SIBO, bacterial overgrowth, or dysbiosis (terms he treats as broadly equivalent in this context). In that pattern, the gut barrier becomes more permeable “between the seam,” allowing bacterial products and other materials to cross into tissue and trigger immune activation and inflammation.
2) COVID-associated permeability related to epithelial cell death (apoptosis)
What appears “unique” in COVID in the graphic he reviews is that permeability may not be primarily from leakage between tight junctions. Instead, he describes evidence suggesting entire intestinal epithelial cells undergo death (apoptosis), creating larger defects where more material can pass through. He associates this pattern with high levels of inflammation and notes it has been described in other high-inflammation medical settings, including severe burns, celiac disease, some chemotherapy regimens, multiple trauma (e.g., a severe car wreck), and (historically) HIV infection before viral control.
In Dr. Nemechek’s framing, this distinction matters because approaches that reduce excess bacteria can help with the SIBO/dysbiosis-driven pattern, but they may not address permeability driven by clusters of epithelial cells dying.
Why intestinal permeability can amplify inflammation
Dr. Nemechek emphasizes the immune density around the small intestine. He notes that a large proportion of the body’s white blood cells are stationed in tissue rather than circulating in blood, and that a substantial portion is associated with the gut. In this context, when the barrier is compromised and bacterial/viral cell wall products or food-related materials cross into tissue, the immune response can be “massive,” fueling inflammation.
Glutamine under inflammatory stress: Dr. Nemechek’s interpretation
Dr. Nemechek then connects high inflammatory demand to glutamine status. He describes glutamine as having a balance between synthesis and consumption in health: multiple tissues can contribute to glutamine production, while organs and systems such as the kidney, brain, gut, and immune cells require it.
In illness—particularly when inflammation is high—he describes glutamine levels declining due to increased consumption. In his interpretation, immune cells can markedly increase glutamine use during high inflammation, creating a glutamine-deficient state. He associates that deficiency with deterioration of the intestinal tract and development of barrier “holes.”
Why he does not expect “SIBO-only” tools to fix this pattern
Dr. Nemechek states that if the problem is primarily excess bacteria and seam-level permeability, tools such as inulin, rifaximin (he pronounces this as “raxan”), or PHGG can help by reducing excess bacteria and thereby reducing that kind of leaky gut.
However, he explicitly cautions that those interventions would not be expected to repair the COVID-associated pattern he is describing—where clusters of epithelial cells die—because the issue is not simply bacterial load. In his view, glutamine is the “primary thing” that repairs that high-inflammation, cell-death-associated barrier disruption.
Clinical observations in children after COVID exposure: early parent-reported outcomes
Dr. Nemechek shares preliminary, practice-based observations from 103 children with autism and developmental delay who were thought to have had COVID (some with documented positive tests; others with presumed exposure and mild illness). He notes that, in his dataset at the time of recording, parents reported that about 65% of these children were doing “much, much better” neurologically, with improvement in autonomic dysfunction.
He also reports gastrointestinal changes that improved in many children, including diarrhea and what he calls postprandial diarrhea (needing to use the bathroom soon after eating). In his experience, improvements were typically noticed within one to two months.
He also emphasizes that about one-third showed no improvement. He notes that this is not surprising, given uncertainty about whether every child truly had a long-term COVID-related inflammatory issue. He describes stopping glutamine if no benefit is seen after one to two months.
Tolerability notes he reports
In this group, Dr. Nemechek reports adverse events in 7% (7 out of 103). He describes these as mild but notable changes such as irritability, increased aggression, or unhappiness. He notes that he would stop glutamine within a few days if this occurred, and symptoms would resolve.
How he uses glutamine in practice (as described in the video)
Dr. Nemechek describes preferring a glutamine powder (rather than capsules) because capsules may not reach the amount he uses. He provides practical reference points for measuring powder (e.g., teaspoon and tablespoon equivalents) and states his dosing regimens in the video fall in a range from about half a teaspoon twice daily up to two teaspoons twice daily, with instructions to follow the dosing calculations shown on his screen.
He explains his goal is to heal the gut barrier relatively quickly, reduce intestinal permeability, and thereby reduce inflammation—supporting improved function in affected children. He also notes that his team is collecting additional feedback, including in adults, and that he has found it “quite effective” for adults as well.
